BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 17158887)

  • 1. A potential role for multiple tissue kallikrein serine proteases in epidermal desquamation.
    Borgoño CA; Michael IP; Komatsu N; Jayakumar A; Kapadia R; Clayman GL; Sotiropoulou G; Diamandis EP
    J Biol Chem; 2007 Feb; 282(6):3640-52. PubMed ID: 17158887
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of lympho-epithelial Kazal-type inhibitor 2 in human skin as a kallikrein-related peptidase 5-specific protease inhibitor.
    Meyer-Hoffert U; Wu Z; Schröder JM
    PLoS One; 2009; 4(2):e4372. PubMed ID: 19190773
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression and localization of tissue kallikrein mRNAs in human epidermis and appendages.
    Komatsu N; Takata M; Otsuki N; Toyama T; Ohka R; Takehara K; Saijoh K
    J Invest Dermatol; 2003 Sep; 121(3):542-9. PubMed ID: 12925213
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective Substrates and Inhibitors for Kallikrein-Related Peptidase 7 (KLK7) Shed Light on KLK Proteolytic Activity in the Stratum Corneum.
    de Veer SJ; Furio L; Swedberg JE; Munro CA; Brattsand M; Clements JA; Hovnanian A; Harris JM
    J Invest Dermatol; 2017 Feb; 137(2):430-439. PubMed ID: 27697464
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LEKTI fragments specifically inhibit KLK5, KLK7, and KLK14 and control desquamation through a pH-dependent interaction.
    Deraison C; Bonnart C; Lopez F; Besson C; Robinson R; Jayakumar A; Wagberg F; Brattsand M; Hachem JP; Leonardsson G; Hovnanian A
    Mol Biol Cell; 2007 Sep; 18(9):3607-19. PubMed ID: 17596512
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of serine protease inhibitors in epidermal keratinocytes is increased by calcium but not 1,25-dihydroxyvitamin D
    Kobashi M; Morizane S; Sugimoto S; Sugihara S; Iwatsuki K
    Br J Dermatol; 2017 Jun; 176(6):1525-1532. PubMed ID: 27797397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Isolation of SPINK6 in human skin: selective inhibitor of kallikrein-related peptidases.
    Meyer-Hoffert U; Wu Z; Kantyka T; Fischer J; Latendorf T; Hansmann B; Bartels J; He Y; Gläser R; Schröder JM
    J Biol Chem; 2010 Oct; 285(42):32174-81. PubMed ID: 20667819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SPINK5 knockdown in organotypic human skin culture as a model system for Netherton syndrome: effect of genetic inhibition of serine proteases kallikrein 5 and kallikrein 7.
    Wang S; Olt S; Schoefmann N; Stuetz A; Winiski A; Wolff-Winiski B
    Exp Dermatol; 2014 Jul; 23(7):524-6. PubMed ID: 24848304
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Keratinocyte-specific mesotrypsin contributes to the desquamation process via kallikrein activation and LEKTI degradation.
    Miyai M; Matsumoto Y; Yamanishi H; Yamamoto-Tanaka M; Tsuboi R; Hibino T
    J Invest Dermatol; 2014 Jun; 134(6):1665-1674. PubMed ID: 24390132
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of Spink6 in mouse skin: the conserved inhibitor of kallikrein-related peptidases is reduced by barrier injury.
    Fischer J; Wu Z; Kantyka T; Sperrhacke M; Dimitrieva O; Koblyakova Y; Ahrens K; Graumann N; Baurecht H; Reiss K; Schröder JM; Proksch E; Meyer-Hoffert U
    J Invest Dermatol; 2014 May; 134(5):1305-1312. PubMed ID: 24352040
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of kallikrein-related peptidases by the serine protease inhibitor of Kazal-type 6.
    Kantyka T; Fischer J; Wu Z; Declercq W; Reiss K; Schröder JM; Meyer-Hoffert U
    Peptides; 2011 Jun; 32(6):1187-92. PubMed ID: 21439340
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel inhibitory activity for serine protease inhibitor Kazal type-3 (Spink3) on human recombinant kallikreins.
    Assis DM; Zalazar L; Juliano MA; De Castro R; Cesari A
    Protein Pept Lett; 2013 Oct; 20(10):1098-107. PubMed ID: 23590280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of human kallikreins 5 and 7 by the serine protease inhibitor lympho-epithelial Kazal-type inhibitor (LEKTI).
    Schechter NM; Choi EJ; Wang ZM; Hanakawa Y; Stanley JR; Kang Y; Clayman GL; Jayakumar A
    Biol Chem; 2005 Nov; 386(11):1173-84. PubMed ID: 16307483
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Attenuated kallikrein-related peptidase activity disrupts desquamation and leads to stratum corneum thickening in human skin equivalent models.
    McGovern JA; Meinert C; de Veer SJ; Hollier BG; Parker TJ; Upton Z
    Br J Dermatol; 2017 Jan; 176(1):145-158. PubMed ID: 27442805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proteolytic activation cascade of the Netherton syndrome-defective protein, LEKTI, in the epidermis: implications for skin homeostasis.
    Fortugno P; Bresciani A; Paolini C; Pazzagli C; El Hachem M; D'Alessio M; Zambruno G
    J Invest Dermatol; 2011 Nov; 131(11):2223-32. PubMed ID: 21697885
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LEKTI is localized in lamellar granules, separated from KLK5 and KLK7, and is secreted in the extracellular spaces of the superficial stratum granulosum.
    Ishida-Yamamoto A; Deraison C; Bonnart C; Bitoun E; Robinson R; O'Brien TJ; Wakamatsu K; Ohtsubo S; Takahashi H; Hashimoto Y; Dopping-Hepenstal PJ; McGrath JA; Iizuka H; Richard G; Hovnanian A
    J Invest Dermatol; 2005 Feb; 124(2):360-6. PubMed ID: 15675955
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SPINK9: a selective, skin-specific Kazal-type serine protease inhibitor.
    Brattsand M; Stefansson K; Hubiche T; Nilsson SK; Egelrud T
    J Invest Dermatol; 2009 Jul; 129(7):1656-65. PubMed ID: 19194479
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Physiological and pathological roles of kallikrein-related peptidases in the epidermis.
    Kishibe M
    J Dermatol Sci; 2019 Aug; 95(2):50-55. PubMed ID: 31279501
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual antibody inhibition of KLK5 and KLK7 for Netherton syndrome and atopic dermatitis.
    Chavarria-Smith J; Chiu CPC; Jackman JK; Yin J; Zhang J; Hackney JA; Lin WY; Tyagi T; Sun Y; Tao J; Dunlap D; Morton WD; Ghodge SV; Maun HR; Li H; Hernandez-Barry H; Loyet KM; Chen E; Liu J; Tam C; Yaspan BL; Cai H; Balazs M; Arron JR; Li J; Wittwer AJ; Pappu R; Austin CD; Lee WP; Lazarus RA; Sudhamsu J; Koerber JT; Yi T
    Sci Transl Med; 2022 Dec; 14(675):eabp9159. PubMed ID: 36516271
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The 420K LEKTI variant alters LEKTI proteolytic activation and results in protease deregulation: implications for atopic dermatitis.
    Fortugno P; Furio L; Teson M; Berretti M; El Hachem M; Zambruno G; Hovnanian A; D'Alessio M
    Hum Mol Genet; 2012 Oct; 21(19):4187-200. PubMed ID: 22730493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.